Company Announcements

Cancellation of Share Premium Account

Source: RNS
RNS Number : 5086J
Diaceutics PLC
24 October 2024
 

24 October 2024

 

Diaceutics plc

 

(the "Company")

 

Cancellation of Share Premium Account

 

 

Belfast and London, 24 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that earlier today the High Court of Justice in Northern Ireland confirmed the cancellation of the sum standing to the credit of the Company's share premium account (the "Reduction of Capital"). The Reduction of Capital will become effective on registration of the Court order at Companies House, which is expected to occur in the next few days.

 

The Reduction of Capital, as described in the AGM Notice that was sent to shareholders on 29 May 2024 and which is available on the Company's website (https://investors.diaceutics.com), was approved by way of a special resolution passed by the shareholders of the Company at the annual general meeting held on 24 June 2024.

 

The purpose of the Reduction of Capital is to create distributable reserves which will provide the Company with flexibility to support, amongst other things, share buy-backs, the funding of the Company's share option schemes and the payment of dividends or other distributions to shareholders in the future.

 

 

 

Enquiries:




Diaceutics PLC  

Tel: +44 (0)28 9040 6500

Ryan Keeling, Chief Executive Officer

investorrelations@diaceutics.com

Nick Roberts, Chief Financial Officer

 


Canaccord Genuity Limited (Nomad & Broker)

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees

 


Alma Strategic Communications

Tel: +44(0)20 3405 0205

Caroline Forde, Kinvara Verdon

 

diaceutics@almastrategic.com

 

 

 

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQKQBQDBDDAKB